8-K: ProKidney Announces Positive Interim Phase 2 Trial Data for REGEN-007 and Provides Clinical Updates

ProKidney's REGEN-007 Phase 2 trial shows promising interim results with stabilized kidney function for 18 months, alongside the resumption of manufacturing and Phase 3 trials.

Summary

• ProKidney announced positive interim results from its Phase 2 REGEN-007 trial, which is evaluating rilparencel, a cell therapy for chronic kidney disease (CKD) caused by diabetes.
• The trial has two groups: Group 1 received two injections of rilparencel three months apart, while Group 2 received a second injection only if triggered by a decline in kidney function or an increase in urine albumin.
• In Group 1, 13 patients with at least 12 months of follow-up after the second injection showed stabilized kidney function for 18 months, with an average eGFR change of -1.3 ml/min/1.73m2 from baseline.
• A subset of 10 patients in Group 1, meeting Phase 3 inclusion criteria, showed an even better average eGFR change of -0.6 ml/min/1.73m2 over 18 months.
• In Group 2, 25 patients received at least one injection, with 12 receiving a second injection based on pre-defined criteria.
• No serious adverse events related to rilparencel were observed across all 49 patients who received at least one injection.
• ProKidney has resumed manufacturing for U.S. and non-European clinical study sites, effective June 1, 2024.
• The company anticipates receiving a QP Declaration of Equivalence to EU GMPs by the end of June 2024, which will allow them to ship rilparencel to European clinical study sites.
• Patient screening has resumed in the PROACT 1 study under an amended protocol, and sites in Spain have been activated for the PROACT 2 study.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a Phase 2 trial, along with the resumption of manufacturing and Phase 3 trials. While there are risks and uncertainties, the overall tone is optimistic and suggests significant progress in the development of a novel therapy for CKD.

Positives

• The interim results from the REGEN-007 Phase 2 trial are promising, showing stabilization of kidney function for 18 months.
• The safety profile of rilparencel is consistent with prior studies and comparable to kidney biopsy.
• The resumption of manufacturing and Phase 3 trials are significant operational milestones.
• The amended protocol for the PROACT 1 study is enriched with higher-risk patients.
• The company is progressing towards receiving a QP Declaration of Equivalence to EU GMPs, which will enable expansion into European clinical study sites.

Negatives

• The document notes that the company's actual results may differ from its expectations, estimates and projections.
• The company faces risks including the inability to maintain its Nasdaq listing, raise financing, or obtain regulatory approvals.
• The document highlights the competitive nature of the biotechnology industry and the challenges of commercializing new therapies.

Risks

• The company may not be able to maintain its Nasdaq listing.
• There is a risk of downturns and a changing regulatory landscape in the biotechnology industry.
• The company may face challenges in raising future financing.
• There is a risk that the company may not obtain regulatory clearance or approval for its products.
• The company may not be able to compete with other companies in the biologics market.
• The size and growth potential of the markets for the company's products are uncertain.
• There are uncertainties inherent in cell therapy research and development, including the timing of clinical studies and regulatory decisions.
• Interim results from clinical programs may not be indicative of future results.
• Geo-political conflicts could impact the company's business.

Future Outlook

The company anticipates providing full results from the REGEN-007 trial in the first half of 2025 and expects to continue enrolling subjects in the PROACT 1 and PROACT 2 Phase 3 studies. They also plan to provide an update on the mechanism of action in the second half of 2025 and anticipate completion of both Phase 3 studies in 2027.

Management Comments

• Bruce Culleton, Chief Executive Officer, stated that the interim results from REGEN-007 are promising and reveal the potential of rilparencel to preserve kidney function in patients with moderate to severe CKD.
• He also noted that this is the first clinical study using bilateral kidney dosing and cryopreserved rilparencel, replicating the approach in the Phase 3 studies.

Industry Context

This announcement is significant in the context of the broader industry trend of developing novel therapies for chronic kidney disease, particularly for patients with diabetes. The results suggest that rilparencel could offer a new approach to preserving kidney function, addressing a critical unmet need in this patient population. The company is competing with other companies developing SGLT2 inhibitors and other therapies for CKD.

Comparison to Industry Standards

• The document compares the results of the REGEN-007 trial to the performance of SGLT2 inhibitors in other clinical trials, such as CREDENCE and EMPA-KIDNEY.
• While SGLT2 inhibitors have shown some benefit in slowing the progression of CKD, they do not prevent the loss of kidney function in advanced stages, with patients losing approximately 4 to 7 eGFR in the first 18 months.
• The REGEN-007 trial showed stabilization of kidney function over 18 months, suggesting a potential advantage over existing therapies.
• The company used an externally developed control arm using data from Dr. Navdeep Tangri to contextualize the REGEN-007 results, matching patients based on 2-year risk of kidney failure and SGLT2 inhibitor usage.
• The matched controls showed a continuous decline in kidney function over 18 months, with an average change of -6.2 ml/min/1.73m2, highlighting the potential benefit of rilparencel.

Stakeholder Impact

• Shareholders may view the positive trial results and operational updates favorably.
• Patients with CKD may benefit from the potential of rilparencel to preserve kidney function.
• Employees may be encouraged by the progress of the company's clinical programs.
• The company's suppliers and partners may see increased activity and potential for future collaboration.

Next Steps

• ProKidney will provide full results from the REGEN-007 trial in the first half of 2025.
• The company will continue enrolling subjects in the PROACT 1 and PROACT 2 Phase 3 studies.
• An update on the mechanism of action is expected in the second half of 2025.
• Completion of both Phase 3 studies is anticipated in 2027.

Key Dates

Keywords

rilparencel, chronic kidney disease, CKD, cell therapy, REGEN-007, Phase 2 trial, Phase 3 trial, eGFR, kidney function, diabetes, PROACT 1, PROACT 2, manufacturing, clinical study, biotechnology